Mark Reinwald1, Peter Markus Deckert1, Oliver Ritter2, Henrike Andresen2, Andreas G Schreyer3, Karsten Henrich Weylandt4, Werner Dammermann5,6, Stefan Lüth5,6. 1. Department of Hematology and Oncology, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany. 2. Department of Cardiology and Pneumology, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany. 3. Department of Radiology, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany. 4. Department of Gastroenterology, Metabolism and Oncology, Brandenburg Medical School Theodor Fontane, 16816 Neuruppin, Germany. 5. Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany. 6. Department of Gastroenterology, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany.
Abstract
(1) Background: Healthcare workers (HCWs) are prone to intensified exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the ongoing pandemic. We prospectively analyzed the prevalence of antibodies against SARS-CoV-2 in HCWs at baseline and follow up with regard to clinical signs and symptoms in two university hospitals in Brandenburg, Germany. (2) Methods: Screening for anti-SARS-CoV-2 IgA and IgG antibodies was offered to HCWs at baseline and follow up two months thereafter in two hospitals of Brandenburg Medical School during the first wave of the COVID-19 pandemic in Germany in an ongoing observational cohort study. Medical history and signs and symptoms were recorded by questionnaires and analyzed. (3) Results: Baseline seroprevalence of anti-SARS-CoV-2 IgA was 11.7% and increased to 15% at follow up, whereas IgG seropositivity was 2.1% at baseline and 2.2% at follow up. The rate of asymptomatic seropositive cases was 39.5%. Symptoms were not associated with general seropositivity for anti-SARS-CoV-2; however, class switch from IgA to IgG was associated with increased symptom burden. (4) Conclusions: The seroprevalence of antibodies against SARS-CoV-2 was low in HCWs but higher compared to population data and increased over time. Screening for antibodies detected a significant proportion of seropositive participants cases without symptoms.
(1) Background: Healthcare workers (HCWs) are prone to intensified exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the ongoing pandemic. We prospectively analyzed the prevalence of antibodies against SARS-CoV-2 in HCWs at baseline and follow up with regard to clinical signs and symptoms in two university hospitals in Brandenburg, Germany. (2) Methods: Screening for anti-SARS-CoV-2IgA and IgG antibodies was offered to HCWs at baseline and follow up two months thereafter in two hospitals of Brandenburg Medical School during the first wave of the COVID-19 pandemic in Germany in an ongoing observational cohort study. Medical history and signs and symptoms were recorded by questionnaires and analyzed. (3) Results: Baseline seroprevalence of anti-SARS-CoV-2IgA was 11.7% and increased to 15% at follow up, whereas IgG seropositivity was 2.1% at baseline and 2.2% at follow up. The rate of asymptomatic seropositive cases was 39.5%. Symptoms were not associated with general seropositivity for anti-SARS-CoV-2; however, class switch from IgA to IgG was associated with increased symptom burden. (4) Conclusions: The seroprevalence of antibodies against SARS-CoV-2 was low in HCWs but higher compared to population data and increased over time. Screening for antibodies detected a significant proportion of seropositive participants cases without symptoms.
Authors: Alessio Mazzoni; Laura Maggi; Manuela Capone; Michele Spinicci; Lorenzo Salvati; Maria Grazia Colao; Anna Vanni; Seble Tekle Kiros; Jessica Mencarini; Lorenzo Zammarchi; Elisabetta Mantengoli; Lorenzo Menicacci; Eleonora Caldini; Sergio Romagnani; Francesco Liotta; Alessandro Morettini; Gian Maria Rossolini; Alessandro Bartoloni; Lorenzo Cosmi; Francesco Annunziato Journal: Eur J Immunol Date: 2020-11-09 Impact factor: 5.532
Authors: N Davidson; J Evans; D Giammichele; H Powell; P Hobson; B Teis; H Glover; K B Guppy-Coles; J Robson Journal: Pathology Date: 2020-09-30 Impact factor: 5.306
Authors: Tom Jefferson; Chris B Del Mar; Liz Dooley; Eliana Ferroni; Lubna A Al-Ansary; Ghada A Bawazeer; Mieke L van Driel; Mark A Jones; Sarah Thorning; Elaine M Beller; Justin Clark; Tammy C Hoffmann; Paul P Glasziou; John M Conly Journal: Cochrane Database Syst Rev Date: 2020-11-20
Authors: Kasper Iversen; Henning Bundgaard; Rasmus B Hasselbalch; Jonas H Kristensen; Pernille B Nielsen; Mia Pries-Heje; Andreas D Knudsen; Casper E Christensen; Kamille Fogh; Jakob B Norsk; Ove Andersen; Thea K Fischer; Claus Antonio Juul Jensen; Margit Larsen; Christian Torp-Pedersen; Jørgen Rungby; Sisse B Ditlev; Ida Hageman; Rasmus Møgelvang; Christoffer E Hother; Mikkel Gybel-Brask; Erik Sørensen; Lene Harritshøj; Fredrik Folke; Curt Sten; Thomas Benfield; Susanne Dam Nielsen; Henrik Ullum Journal: Lancet Infect Dis Date: 2020-08-03 Impact factor: 25.071
Authors: Kathleen G Beavis; Scott M Matushek; Ana Precy F Abeleda; Cindy Bethel; Carlissa Hunt; Stephanie Gillen; Angelica Moran; Vera Tesic Journal: J Clin Virol Date: 2020-05-23 Impact factor: 3.168
Authors: Anke Hildebrandt; Oktay Hökelekli; Lutz Uflacker; Henrik Rudolf; Michael Paulussen; Sören G Gatermann Journal: Int J Environ Res Public Health Date: 2022-02-19 Impact factor: 3.390
Authors: Brian T Montague; Matthew F Wipperman; Erica Chio; Rowena Crow; Andrea T Hooper; Meagan P O'Brien; Eric A F Simões Journal: Sci Rep Date: 2022-09-02 Impact factor: 4.996